[
  {
    "ts": null,
    "headline": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
    "summary": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=9d488e18d7a2ae4ca3b4f12786a4fa78c1857b712e3bd15e843057dfc3511e3e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759333204,
      "headline": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
      "id": 136952512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "HOLX vs. IDXX: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=9d488e18d7a2ae4ca3b4f12786a4fa78c1857b712e3bd15e843057dfc3511e3e"
    }
  },
  {
    "ts": null,
    "headline": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
    "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
    "url": "https://finnhub.io/api/news?id=aded1309859837a9be38074d140583cef3bd367dcf064e673234432713cbe87d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759324200,
      "headline": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
      "id": 136947441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
      "url": "https://finnhub.io/api/news?id=aded1309859837a9be38074d140583cef3bd367dcf064e673234432713cbe87d"
    }
  },
  {
    "ts": null,
    "headline": "VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode.",
    "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT RECENT NEWS VolitionRx’s (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority that was described during the second quarter 2025 conference call in August. During the call, CEO Cameron Reynolds relayed that the company was in confidential",
    "url": "https://finnhub.io/api/news?id=684e0237babc19894345cbf7b8f204ef4099f576572cfde6a5d82248440f3374",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759318200,
      "headline": "VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with Hologic Diagenode.",
      "id": 136952655,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT SIGNIFICANT RECENT NEWS VolitionRx’s (NYSE:VNRX) announcements of two significant licensing agreements in September 2025 represent the materialization of a key priority that was described during the second quarter 2025 conference call in August. During the call, CEO Cameron Reynolds relayed that the company was in confidential",
      "url": "https://finnhub.io/api/news?id=684e0237babc19894345cbf7b8f204ef4099f576572cfde6a5d82248440f3374"
    }
  }
]